Shattuck Labs, Inc. Impairment of Long-Lived Assets to be Disposed of
Shattuck Labs, Inc. (STTK) reported Impairment of Long-Lived Assets to be Disposed of of $81.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2026-03-05
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2025-12-31 was $81.00K, a 8.00% increase year-over-year.
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2025-09-30 was $0.00.
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-12-31 was $75.00K.
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2024-09-30 was $0.00.
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for fiscal 2025 was $81.00K, a 63.51% decline from fiscal 2024.
- Shattuck Labs, Inc. impairment of long-lived assets to be disposed of for fiscal 2024 was $222.00K.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|
| 2025-12-31 | $81.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $81.00K derived: sum of 2 quarters · filed 2026-03-05 | $81.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2024-12-31 | $75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $75.00K derived: sum of 2 quarters · filed 2026-03-05 | $222.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $147.00K 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |